Literature DB >> 20183546

Psychometric development of the retinopathy treatment satisfaction questionnaire (RetTSQ).

Leonie S Brose1, Clare Bradley.   

Abstract

Objectives were to evaluate the psychometric properties and to determine optimal scoring of the retinopathy treatment satisfaction questionnaire (RetTSQ) in a cross-sectional study of 207 German patients with diabetic retinopathy and a wide range of treatment experience. Forty patients (19%) also had clinically significant macular oedema. Principal components analysis was used to identify factor structures and Cronbach's alpha to assess internal consistency reliabilities. Two highly reliable subscales represented negative versus positive aspects of treatment (both alpha = 0.85). A highly reliable total score can be calculated (alpha = 0.90). Construct validity was examined by testing expected relationships of RetTSQ scores with visual impairment, stage of diabetic retinopathy, additional impact of macular oedema, SF-12 scores and scores of the RetDQoL measure of quality of life in diabetic retinopathy. Worse impairment, worse diabetic retinopathy and macular oedema were associated with less treatment satisfaction. RetTSQ scores correlated moderately with SF-12 scores (r: 0.33-0.53, p < 0.001) and RetDQoL scores (r: 0.43-0.51, p < 0.001). Answers to an open-ended question indicated no need for additional items. Repeating the analyses in a subsample with experience of more intense treatment showed very similar results. It can be concluded that the RetTSQ is valid and reliable for people with diabetic retinopathy with or without macular oedema who have experienced different treatments.

Entities:  

Mesh:

Year:  2009        PMID: 20183546     DOI: 10.1080/13548500903431485

Source DB:  PubMed          Journal:  Psychol Health Med        ISSN: 1354-8506            Impact factor:   2.423


  12 in total

1.  Treatment satisfaction of patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents.

Authors:  Theodoros P Marakis; Chrysanthi Koutsandrea; Klio I Chatzistefanou; Yannis Tountas
Journal:  Int Ophthalmol       Date:  2017-03-11       Impact factor: 2.031

2.  Psychometric evaluation of a multi-dimensional measure of satisfaction with behavioral interventions.

Authors:  Souraya Sidani; Dana R Epstein; Mary Fox
Journal:  Res Nurs Health       Date:  2017-08-31       Impact factor: 2.228

3.  A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study).

Authors:  J Ramu; Y Yang; G Menon; C Bailey; N Narendran; C Bunce; A Quartilho; A T Prevost; P Hykin; S Sivaprasad
Journal:  Eye (Lond)       Date:  2015-10-23       Impact factor: 3.775

4.  Patient Satisfaction of Intravitreal Bevacizumab Injection Services at a Referral Center.

Authors:  Maryam Shayan; Sare Safi; Saeed Karimi; Mehdi Yaseri
Journal:  J Curr Ophthalmol       Date:  2021-03-26

5.  Development of a questionnaire to assess patient satisfaction with allergen-specific immunotherapy in adults: item generation, item reduction, and preliminary validation.

Authors:  Jose Luis Justícia; Eva Baró; Victoria Cardona; Pedro Guardia; Pedro Ojeda; José Maria Olaguíbel; José Maria Vega; Carmen Vidal
Journal:  Patient Prefer Adherence       Date:  2011-05-24       Impact factor: 2.711

6.  Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting.

Authors:  Rishma Gohil; Roxanne Crosby-Nwaobi; Angus Forbes; Ben J Burton; Philip Hykin; Sobha Sivaprasad
Journal:  Patient Prefer Adherence       Date:  2016-05-26       Impact factor: 2.711

Review 7.  Measuring the burden of treatment for chronic disease: implications of a scoping review of the literature.

Authors:  Adem Sav; Asiyeh Salehi; Frances S Mair; Sara S McMillan
Journal:  BMC Med Res Methodol       Date:  2017-09-12       Impact factor: 4.615

8.  Health-related quality of life, visual function and treatment satisfaction following intravitreal dexamethasone implant for diabetic macular edema.

Authors:  Jayashree Ramu; Irini Chatziralli; Yit Yang; Geeta Menon; Clare Bailey; Michael Eckstein; Phil Hykin; Sobha Sivaprasad
Journal:  Patient Prefer Adherence       Date:  2017-03-17       Impact factor: 2.711

9.  Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial.

Authors:  Sobha Sivaprasad; A Toby Prevost; James Bainbridge; Rhiannon Tudor Edwards; David Hopkins; Joanna Kelly; Phil Luthert; Caroline Murphy; Jayashree Ramu; Negin Sarafraz-Shekary; Joana Vasconcelos; Beverley White-Alao; Philip Hykin
Journal:  BMJ Open       Date:  2015-09-14       Impact factor: 2.692

10.  Design and development of the MacTSQ measure of satisfaction with treatment for macular conditions used within the IVAN trial.

Authors:  Jan Mitchell; Clare Bradley
Journal:  J Patient Rep Outcomes       Date:  2018-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.